Respiratory syncytial virus DNA vaccine - Fresh Tracks Therapeutics
Latest Information Update: 14 Sep 2022
Price :
$50 *
At a glance
- Originator Vical
- Developer Fresh Tracks Therapeutics
- Class Gene therapies; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
- 31 Oct 2002 Discontinued - Preclinical for Respiratory syncytial virus infections in USA (Injection)